Počet záznamů: 1
Novel arylazopyrazole inhibitors of cyclin-dependent kinases
- 1.
SYSNO ASEP 0454915 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Novel arylazopyrazole inhibitors of cyclin-dependent kinases Tvůrce(i) Jorda, Radek (UEB-Q) ORCID, RID
Schütznerová, E. (CZ)
Cankař, P. (CZ)
Brychtová, Veronika (UEB-Q)
Navrátilová, Jana (UEB-Q)
Kryštof, Vladimír (UEB-Q) RID, ORCIDZdroj.dok. Bioorganic & Medicinal Chemistry. - : Elsevier - ISSN 0968-0896
Roč. 23, č. 9 (2015), s. 1975-1981Poč.str. 7 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova Cyclin-dependent kinases ; Inhibitor ; Cell cycle Vědní obor RIV CE - Biochemie CEP GAP305/12/0783 GA ČR - Grantová agentura ČR GA14-19590S GA ČR - Grantová agentura ČR LO1204 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Institucionální podpora UEB-Q - RVO:61389030 UT WOS 000352698700007 DOI 10.1016/j.bmc.2015.03.025 Anotace Here, we describe new 4-arylazo-3,5-diamino-1H-pyrazole derivatives developed from CAN508, one of the first inhibitors to show preference for transcriptional regulator cyclin-dependent kinase 9. By substituting nitrogen in the pyrazole ring and employing a heteroatom in the 4-aryl ring, we obtained more potent derivatives differing in their CDK-selectivity profiles. The antiproliferative and anti-CDK kinase activities of the novel arylazopyrazoles were examined. The cellular effect of compound IVc was studied on MCF-7 cells synchronized by various methods and compared with other selective CDK inhibitors. The results demonstrated that IVc shows a preference for CDK4 and CDK1. In contrast to cytostatic effects induced by IVc in MCF-7 and K562 cells, we observed apoptotic activities in the RPMI-8226 cell line, which were confirmed by detecting active caspases by different biochemical assays. Pracoviště Ústav experimentální botaniky Kontakt David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Rok sběru 2016
Počet záznamů: 1